A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment-Resistant Depression Registry investigated whether adjunctive vagus nerve stimulation (VNS) with treatment as usual in depression has superior long-term outcomes compared with treatment as usual only. METHOD: This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients who were experiencing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had three or more depressive episodes (including the current episode), and who had failed four or more depression treatments (including ECT). Patients with a history of psychosis or rapid-cycling bipolar disorder were excluded. The primary efficacy measure was response rate, defined as a decrease of ≥50% in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at any postbaseline visit during the 5-year study. Secondary efficacy measures included remission. RESULTS: Patients had chronic moderate to severe depression at baseline (the mean MADRS score was 29.3 [SD=6.9] for the treatment-as-usual group and 33.1 [SD=7.0] for the adjunctive VNS group). The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%). A subanalysis demonstrated that among patients with a history of response to ECT, those in the adjunctive VNS group had a significantly higher 5-year cumulative response rate than those in the treatment-as-usual group (71.3% compared with 56.9%). A similar significant response differential was observed among ECT nonresponders (59.6% compared with 34.1%). CONCLUSIONS: This registry represents the longest and largest naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides additional evidence that adjunctive VNS has enhanced antidepressant effects compared with treatment as usual in this severely ill patient population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, stimulation of the vagus nerve (one of the core interoceptive neural pathways) has been successfully used as a means of treating depression (Aaronson et al., 2017).”
From Atypical interoception as a common risk factor for psychopathology: A review (2021) · cites this paper as Aaronson et al., 2017
In the citing paper
“This was even the case in patients with comorbid depression and anxiety who are frequent non-responders in trials on antidepressant drugs.”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
In the citing paper
“Further, a 5-year prospective observational study which compared the effects of treatment as usual and VNS as adjunctive treatment with treatment as usual only in treatment-resistant depression, showed a better clinical outcome and a higher remission rate in the VNS group (116).”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
Citations
Cites
1 retracted
Hollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179 · cited 1×
“Given ethical concerns about following such a severely ill patient population over a 5-year period, the registry had a naturalistic, observational design and did not randomly assign patients to the treatment groups (22, 23).”
Self-citationRetractedThe central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1976) · Medical Entomology and Zoology · Cited by 8,899
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 1×
“TheMontgomeryÅsberg Depression Rating Scale (MADRS) (12) (administered by central raters), the Quick Inventory of Depressive Symptomatology–Self Report (QIDS-SR) (13, 14), the CGI improvement (CGI-I) score, and the patient-rated Frequency, Intensity, andBurdenofSideEffectsRating scale (15) were administered, and data…”
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 10×
“Secondary efficacy endpoints included response based on a CGI-I score of 1 or 2 at a postbaseline visit and an improvement of$50% frombaseline on theQIDS-SR; remission, based on aMADRS score #9 at a postbaseline visit, a QIDS-SR score #5 at a postbaselinevisit, andaCGI-I scoreof 1 at apostbaselinevisit; and duration o…”
MethodInfluentialThe Central Role of the Propensity Score in Observational Studies for Causal Effects
Rosenbaum, P. R., & Rubin, D. B. (1983) · Biometrika · doi:10.2307/2335942 · Cited by 3,261
Research works printed but not linked: 2
- Rush AJ, 2009, CNS Drugs, 23, 627
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
Cited by
Items 201–300 of 391
Ko, D. W. K. (2021) · Autonomic Neuroscience · doi:10.1016/j.autneu.2021.102858 · Cited by 8
Treatment-Resistant Depression
Cusin, C., & Peyda, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_1 · Cited by 9
Why is deep brain stimulation for treatment-resistant depression a needed treatment option?
Riva‐Posse, P. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-0004 · Cited by 9
Chen, Y., Pan, C., Cheng, S., Li, C., Zhang, H., Zhang, Z., Zhang, J., Yao, Y., Meng, P., Yang, X., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02042-5 · Cited by 9
“Over the past several decades, the amount of people with depression have increased leading to a growing concern in mental health research around the world [2].”
BackgroundUltrasound stimulation of the vagus nerve as a treatment modality for anxiety
Goyal, M., Goyal, R., & Sanguinetti, J. L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1376140 · Cited by 7
Sackeïm, H. A., Conway, C. R., Aaronson, S. T., Bunker, M. T., Gordon, C., Lee, Y.-C. (., Shy, O., Majewski, S., Tran, Q., & Rush, A. J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.124 · Cited by 8
Self-citationVagus nerve stimulation in various stages of stroke and associated functional impairments: A review
Wang, L., Xu, Q., Luo, M., Xing, X., Wang, J., Liang, Y., Zhang, J., Sheng, R., Niu, S., & Wang, Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.04.037 · Cited by 7
Sarkar, S., Maparu, K., & Aran, K. R. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10703-2 · Cited by 8
The profile of symptom change with transcranial magnetic stimulation for major depressive disorder
Hutton, T. M., Aaronson, S. T., Carpenter, L. L., Pages, K. P., Rush, A. J., & Sackeïm, H. A. (2024) · Transcranial magnetic stimulation . · doi:10.1016/j.transm.2024.100074 · Cited by 10
Self-citationTreatment resistant depression
Vaccarino, S. R., & Kennedy, S. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00003-4 · Cited by 8
Developing Precision Invasive Neuromodulation for Psychiatry
Bormann, N. L., Trapp, N. T., Narayanan, N. S., & Boes, A. D. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20100268 · Cited by 8
“While these examples of immediate effects of stimulation are encouraging with regard to establishing causal inferences, it is also well established that many neuromodulation therapies take weeks or months before a therapeutic benefit is noted (21, 52, 53).”
BackgroundVagus nerve stimulation: An update of currently registered clinical trials on ClinicalTrials.gov
Horowitz, M. A., Sussman, J. H., Zomalan, B., Rendler, J., Singh, A., Birouty, N., Seaton, M. P., Patel, S., Gendreau, J. L., & Abraham, M. E. (2026) · Surgical Neurology International · doi:10.25259/sni_771_2025 · Cited by 6
“[Table 2].”
InfluentialCost‐Effectiveness of Depression Screening for Otolaryngology–Head and Neck Surgery Residents
Kligerman, M. P., Devine, E. E., Bentzley, J. P., & Megwalu, U. C. (2020) · The Laryngoscope · doi:10.1002/lary.28780 · Cited by 6
Wilkinson, S. T., Diaz, D. T., Rupp, Z. W., Kidambi, A., Ramírez, K. L., Flores, J. M., Avila-Quintero, V. J., Rhee, T. G., Olfson, M., & Bloch, M. H. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021006 · Cited by 9
Aboubakr, O., Domenech, P., Heurtebise, I., Gaillard, R., Guy-Rubin, A., Carron, R., Duriez, P., Gorwood, P. A. P. M., Vinckier, F., Pallud, J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1305603 · Cited by 6
Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression
Widge, A. S., Malone, D. A., & Dougherty, D. D. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16302 · Cited by 8
Self-citationGillespie, C. F., Szabo, S. T., & Nemeroff, C. B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00036-9 · Cited by 7
Enlarged cross-sectional area of the left vagus nerve in patients with major depressive disorder
Schreiber, L. S., Wozniak, D., Scheller, E., Böttcher, E., Pelz, J. O., & Schmidt, F. M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1237983 · Cited by 6
Sagui, E., Claverie, D., Bidaut, W., & Grélot, L. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04392-7 · Cited by 6
“Invasive peripheral nerve stimulation, most often through the vagus nerve, has proven to be an effective therapeutic option for treating drug-refractory illnesses such as epilepsy and depression [1, 2].”
BackgroundCheng, W., Fang, K., Ouyang, X., Jin, L., Song, Y., & Yu, B. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105871 · Cited by 6
“…significant benefits in patients with various brain diseases, including refractory epilepsy, refractory depression, cluster headache and migraine (Aaronson et al., 2017; Silberstein et al 2016; Tassorelli et al., 2018; Fan et al., 2019), and has been approved by the Food and Drug Administration…”
Electrical Stimulation of Nerves and Muscles
Park, K. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-20784-6_15 · Cited by 7
Long-term relief of intractable hiccups with vagal nerve stimulation
Vloo, P. D., Dallapiazza, R. F., Lee, D. J., Zurowski, M., Peng, P., Chen, R. E., & Hodaie, M. (2018) · Brain stimulation · doi:10.1016/j.brs.2018.08.002 · Cited by 6
Sackeïm, H. A. (2021) · Journal of Ect · doi:10.1097/yct.0000000000000745 · Cited by 6
Interventional psychiatry: the elephants in the room
Padberg, F., Burkhardt, G., Goerigk, S. A., & Brunoni, A. R. (2022) · Brazilian Journal of Psychiatry · doi:10.47626/1516-4446-2022-0044 · Cited by 8
Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions
Schatzberg, A. F., & Fountoulakis, K. Ν. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250745 · Cited by 6
Vagal Nerve Stimulation for Patients With Stress-Related Psychiatric Disorders and Addictions
Bremner, J. D. (2023) · Journal of Health Service Psychology · doi:10.1007/s42843-023-00089-6 · Cited by 5
Kumagai, S., Shiramatsu, T. I., Kawai, K., & Takahashi, H. (2025) · Frontiers in Neural Circuits · doi:10.3389/fncir.2025.1568655 · Cited by 6
Nutrition is Associated with Violent and Criminal Behaviors
Asil, E., & Erkmen, E. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00668-7 · Cited by 5
“Similar studies have also reported that vagus nerve stimulation is a highly effective method for treating depression [ 21–23].”
Shpaner, M., Tulipani, L. J., Bishop, J. H., & Naylor, M. R. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0126-5 · Cited by 5
Segura‐Aguilar, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822120-4.00001-0 · Cited by 5
In vivo peripheral nerve activation using sinusoidal low‐frequency alternating currents
Alhawwash, A., Muzquiz, M. I., Richardson, L. A., Vetter, C., Smolik, M., Goodwill, A. G., & Yoshida, K. (2022) · Artificial Organs · doi:10.1111/aor.14347 · Cited by 5
“In this study, we aim to (1) explore and provide experimental evidence that the LFAC waveform is able to activate ANS nerve fibers within mammalian cervical vagus nerve using the HB reflex as a biomarker, and (2) determine whether the threshold of activation is a function of the applied LFAC frequency.”
MethodNeuromodulation in Geriatric Psychiatry: an Update
Franklin, C. E., Behlke, L. M., & Freedberg, A. (2025) · Current Geriatrics Reports · doi:10.1007/s13670-025-00439-w · Cited by 4
Zhang, S., He, H., Li, X., & Guo, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1615635 · Cited by 4
Recent Advances in Multimodal Non-Pharmacological Interventions for Late-Life Depression
Xu, T., Mao, Y., Wang, Y., Gong, Y., & Yu, E. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s558969 · Cited by 4
“61 Transcutaneous auricular VNS, a non-invasive alternative, can prevent the invasive risk and high cost of VNS by modifying the topology of brain networks, which can effectively alleviate the symptoms of depression.”
A deep representation learning model to predict response to vagus nerve stimulation
Suresh, H., Mithani, K., Li, V., Latypov, T. H., Warsi, N. M., Wong, S. M., Erdman, L., Kang, J., Germann, J., Gouveia, F. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71555-0 · Cited by 4
“This convergence implicates serotonergic circuits as putative mediatorsof VNSef fi cacy in epilepsyandraises thepossibilitythat similar mechanisms may contribute to therapeutic bene fi t in other conditions treated with VNS, such as drug-resistant major depressive disorder 53 .”
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access
Karp, J. F., Brinton, R. D., Fournier, J. C. J., Harding, L., Jha, M. K., Lenze, E. J., Mathew, S. J., Meltzer-Brody, S. E., Mohr, D. C., Riva‐Posse, P., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.psprmdd2408ah · Cited by 5
“29 RECOVER is a large, sham-controlled, randomized trial to evaluate the efficacy of adjunctive treatment with surgically implanted VNS therapy in improving depressive symptoms and health outcomes.”
Alhawwash, A., Horn, M. R., Lazorchak, N., & Yoshida, K. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/adafdc · Cited by 4
Kavakbasi, E., Kraus, C., Reif-Leonhard, C., Blackwell, J.-M., Dibué, M., Treiber, M., Achten, S., & Baune, B. T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.047 · Cited by 4
Colle, R., Tayeb, A. E. K. A., Delhay, L., Boniface, B., Gasnier, M., Martin, S., Domenech, P., Fargeot, C., Choucha, W., Aghakhani, N., et al. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.03.003 · Cited by 4
“Indeed, available studies of VNS in patients with treatment resistant MDE (two randomized controlled trials, four observational studies) excluded MDE patients with psychotic features [3].”
BackgroundInfluentialInfluence of Vagus Nerve Stimulation on Mood and Associated Disorders
Bottari, S. A., Rodriguez, A., & Williamson, J. B. (2023) · Neuromethods · doi:10.1007/978-1-0716-3465-3_7 · Cited by 6
Vagusnervstimulation (VNS) als Behandlungsoption für Depressionen
Kavakbasi, E., & Baune, B. T. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2165-7860 · Cited by 4
Migchels, C., Obbels, J., McAllister-Williams, H., Demyttenaere, K., & Sienaert, P. A. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001001 · Cited by 4
Predictors of response for vagus nerve stimulation in treatment-resistant depression
de León-Martínez, V., Drysdale, A. T., Conway, C. R., & Aaronson, S. T. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.05.001 · Cited by 4
Self-citationPotential Anti-Depressive Treatment Maneuvers from Bench to Bedside
Cai, M., Wang, H., & Zhang, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_15 · Cited by 8
Costa, T. D. S., Hall, B., Hill, S., Teama, R., Romaine, E., Ahmed, S., McKinnon, I., Watson, S., Bagnall, A. J., Kenny, R. P. W., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261433212 · Cited by 4
“Only three cohort studies reported a substantial proportion of participants with bipolar disorder (Aaronson et al., 2017; Lemogne et al., 2013; Murray-Thomas et al., 2013).”
Yu, Y., Wang, Z., Kroemer, N. B., Zhang, L., Lü, L., & Sun, J. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.10.037 · Cited by 3
Ziadi, Y., & Park, T. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101605 · Cited by 3
McAllister-Williams, H., Alva, G., Banov, M. D., Conway, C. R., Cusin, C., de Beer, J. C., Demyttenaere, K., Domany, Y., Domenech, P., Dougherty, D. D., et al. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s554007 · Cited by 3
Self-citationFrom lobotomy to connectomics: a critical review of contemporary psychosurgery
González, V., Rumià, J., Brell, M., Roset, C., de Miguel, J., Arboleya, S., Aguirre, I., Alegre, D., Goliney, V. G., & Ibáñez, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1785333 · Cited by 3
“The largest observational study (n=795, 5-year follow-up) reported cumulative response rates of 68% in the VNS group versus 41% with treatment as usual and remission rates 43% versus 26% (263).”
Therapeutic Neuromodulation toward a Critical State May Serve as a General Treatment Strategy
Arvin, S., Yonehara, K., & Glud, A. N. (2022) · Biomedicines · doi:10.3390/biomedicines10092317 · Cited by 3
Dell’Osso, B. M., Oldani, L., Grancini, B. M., Dario, A., & Altamura, A. C. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s161062 · Cited by 3
“4,12 16–18 In order to provide further evidence about the long-term efficacy and tolerability of VNS in TRD, the present report describes the 10-year follow-up results of two Italian patients with TRD implanted with VNS.”
Vagus Nerve Stimulation as a Treatment for Catatonia: A Hypothesis
Zilles‐Wegner, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00086 · Cited by 3
“treatment-as-usual group in terms of significantly higher response and remission rates in this difficult to treat population (9).”
BackgroundA pacemaker for happiness – Transcutaneous vagus nerve stimulation in depression
Thanarajah, S. E., & Reif, A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.05.008 · Cited by 3
Recognition of others’ interoceptive states in those with and without eating disorders
Gajperia, C., McBride, J., Treasure, J. L., Cardi, V., & Brewer, R. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05615-4 · Cited by 4
“…conditions [5, 6], such as Autism Spectrum Disorder [7–10], Attention-Deficit/Hyperactivity Disorder [11], Obsessive Compulsive Disorder [12, 13], schizophrenia [14], alcohol and substance abuse [15–17], depression [18–22], anxi - ety and panic disorder [22–24], and Eating Disorders (EDs) [25, 26].”
BackgroundRafe, M. R., Waris, A., & Saha, P. (2025) · Health Science Reports · doi:10.1002/hsr2.70370 · Cited by 3
Khan, A., Ahmed, R., Kotapati, V. P., Dar, S. K., Qamar, I., Jafri, A., Ibrahim, M., Kumar, P., & Begum, G. (2018) · International Journal of Medicine and Public Health · doi:10.5530/ijmedph.2018.3.26 · Cited by 4
Roh, S., Lee, K. S., Choi, S., & Kim, J. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.3.548 · Cited by 3
“Treatment response was defined as the proportion of patients who were rated “ very much improved ” or “ much improved ” by the investigators according to the CGI-I scale, as applied in previous PMS studies [16-18].”
Riva‐Posse, P., & Figee, M. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.01.024 · Cited by 2
Idowu, O., Fatoye, E. O., Aderinto, N., Abraham, I. C., Olatunji, G. D., & Kokori, E. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00360-1 · Cited by 2
“Aaronson et al. (2017) [ 8 ], the observed a significant partial response (≥ 30% symptom improvement) on the CGI-I ( p < 0.001) and QIDS-C ( p = 0.006) for active VNS compared to sham.”
InfluentialDong, S., Hao, F., Xue, B., Wu, S., Zhong, R., Liao, Z., Han, H., & Fang, X. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250201 · Cited by 2
Conway, C. R., Sackeïm, H. A., Rush, A. J., Bunker, M. T., Gordon, C., Kriedt, C. L., & Aaronson, S. T. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20251339 · Cited by 2
Self-citationKomorbidität Depression bei Epilepsie
von Oertzen, T. J. (2017) · Clinical Epileptology · doi:10.1007/s10309-017-0149-7 · Cited by 2
“Auch war die durchschnittliche Zeit mit Behandlungserfolg in der Gruppe der VNS-Behandlung (12 Monate) verglichen mit der Treatment-asusual-Gruppe (7 Monte) signifikant verlängert [35].”
BackgroundNeurocircuitry-Based Treatments for Major Depressive Disorder
Giacobbe, P., Mithani, K., Bhat, V., & Meng, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00009-4 · Cited by 3
Fetzer, S., & Ortler, M. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106707 · Cited by 2
Ethical Issues in Vagus Nerve Stimulation and Deep Brain Stimulation
Heyman-Kantor, R., & Cockerill, R. G. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210031 · Cited by 2
Neuropsychiatric Treatments for Epilepsy: Nonpharmacological Approaches
Lopez, M., & Kanner, A. M. (2022) · Seminars in Neurology · doi:10.1055/s-0042-1742582 · Cited by 2
Can Deep Brain Stimulation Be a Promising Treatment for Treatment-Resistant Depression?
Nazanin, A., & Ijeuma, N. (2023) · International Journal of Depression and Anxiety · doi:10.23937/2643-4059/1710036 · Cited by 2
Yuruk, D., Özger, C., Garzon, J. F., Nakonezny, P. A., Voort, J. L. V., & Croarkin, P. E. (2024) · Brain and Behavior · doi:10.1002/brb3.3452 · Cited by 2
“However, VNS and DBS have not been rigorously studied in younger patients.”
MethodInfluentialClinical experience implanting a miniature externally powered vagus nerve stimulator
Epperson, J. D., Foreman, M. L., Naftalis, R. C., Hamilton, R. G., Powers, M. B., Gallaway, H. L., dePrisco, G., Hays, S. A., Kilgard, M. P., Rennaker, R. L., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00625 · Cited by 2
“Subsequently, in 2005, VNS received approval for the treatment of depression in individuals who did not responded to conventional therapies [9].”
Stimulating the brain: a primer
Opri, E., & Cernera, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24824-5.00007-7 · Cited by 2
Novel Neurostimulation Therapeutic Approaches for Treatment-Resistant Psychiatric Disorders
Koek, R. J., Roach, J., Athanasiou, N., & Korotinsky, A. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_22 · Cited by 3
Neurosurgery for Mental Disorder
Matthews, K., & Matthews, C. (2019) · Cambridge University Press eBooks · doi:10.1017/9781911623175.016 · Cited by 2
Vagus Nerve Stimulation for Treatment-Resistant Depression: Current Status of This Novel Treatment
Conway, C. R., Hristidis, V. C., Gott, B. M., & Willie, J. T. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220620-01 · Cited by 2
Self-citationSantistevan, A. C., Moadab, G., Fiske, O., Nord, C., Isaacowitz, D. M., & Bliss‐Moreau, E. (2023) · Psychophysiology · doi:10.1111/psyp.14410 · Cited by 2
Psychodynamically Informed Brain Stimulation: Building a Bridge from Brain to Mind
Austelle, C. W., & Seery, E. (2024) · The American Journal of Psychoanalysis · doi:10.1057/s11231-024-09444-y · Cited by 2
“VNS has a lower rate of relapse compared to treatment as usual (Aaronson et al., 2017), an extraordinary feat when considering the high rate of relapse with other biological treatments.”
Philip, N. S., & Brunoni, A. R. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.03.001 · Cited by 2
“[8,9]).”
Is the vagus nerve the “MVP” in the brain–body axis?
Rodrigues, G. D. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-024-01042-3 · Cited by 1
“In treatment-resistant depression, for instance, VNS resulted in superior outcomes in the effectiveness of depressive symptoms and mortality over 5 years compared with standard pharmacological alone [11].”
The role of torso stiffness and prediction in the biomechanics of anxiety: a narrative review
Chin, S. (2024) · Frontiers in Sports and Active Living · doi:10.3389/fspor.2024.1487862 · Cited by 3
Application of vagal nerve stimulation to post-traumatic stress disorder
Wittbrodt, M. T., Gurel, N. Z., Inan, O. T., Mehta, P. K., & Bremner, J. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816996-4.00011-3 · Cited by 2
Palmer, C., Vieira, N., Collins, E., Dancy, M. M., Chasen, J., & George, M. S. (2025) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20240213 · Cited by 1
Managing the risk of suicide in people with treatment-resistant depression
Franz, P. J., & Alpert, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00039-6 · Cited by 1
Intraoperative Laryngeal Muscle and Heart Rate Responses to Implanted Vagus Nerve Stimulation
Turk, K. M., Mohsenian, K. J., Peters, J. J., Southwell, D. G., Grill, W. M., & Pelot, N. A. (2026) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2026.02.010 · Cited by 1
Pigato, G., Olivo, D., Collantoni, E., Manara, R., Librizzi, G., Bresolin, N., Landi, A., & Sambataro, F. (2025) · Journal of Ect · doi:10.1097/yct.0000000000001198 · Cited by 1
Hou, Y., Guo, X., Wang, X., Wang, Y., Zhang, W., Ran, J., Xu, D., Zhang, Y., Jiang, Y., Lin, F., et al. (2026) · Small · doi:10.1002/smll.202512099 · Cited by 1
A guide to neuromodulation in drug‐resistant epilepsy
Parikh, P., Dolezawa, I., Hegde, M., Imbach, L., Lundstrom, B. N., Pizzo, F., Rao, V. R., Singh, J., Southwell, D. G., Watanabe, S., et al. (2026) · Epileptic Disorders · doi:10.1002/epd2.70221 · Cited by 1
Baek, J. H., & Cho, C. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0144 · Cited by 1
Nahm, W. J., Kim, K., NamGung, E., Koo, J., Han, Y., & Falanga, V. (2026) · Experimental Dermatology · doi:10.1111/exd.70297 · Cited by 1
Wang, G., Zhou, J., Yang, J., & Zhang, X.-H. (2018) · Asia Pacific Journal of Clinical Trials Nervous System Diseases · doi:10.4103/2542-3932.226186 · Cited by 1
Are modern neuromodulation therapies too precise?
McDonald, W. M. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.08.001 · Cited by 2
Ideas on a possible neural pathway in depression
Badihian, N. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110688 · Cited by 1
Ivanov, M. V., Stanovaya, V. V., Катышев, С. А., Yanushko, M. G., Второв, А. В., Клочков, М. Н., Ляскина, И. Ю., Нарышкин, А. Г., Galanin, I. V., Шаманина, М. В., et al. (2021) · Психиатрия психотерапия и клиническая психология · doi:10.34883/pi.2021.12.2.015 · Cited by 1
Difficult-to-Treat Depression and the Role of Vagus Nerve Stimulation
McAllister-Williams, H., & Costa, T. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220622-01 · Cited by 1
Psychopharmacotherapy of Depressive Disorders
Kavakbasi, E., & Baune, B. T. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_427 · Cited by 1
Therapiemöglichkeiten der Depression nach Non-Response: Ein Update für die Praxis
Walter, H., Haaf, R., & Köhler, S. (2023) · Nervenheilkunde · doi:10.1055/a-2103-7920 · Cited by 1
“[52] Aaronson ST, Sears P, Ruvuna F et al.”
BackgroundKavakbasi, E., Bauermeister, H., Lemcke, L., & Baune, B. T. (2024) · Brain Sciences · doi:10.3390/brainsci14020159 · Cited by 1
“These results are in line with those of other reports suggesting a better response to VNS in previous ECT responders than in non-responders [13].”
BackgroundResultInfluentialInterventional therapeutics in psychiatry: Beyond psychopharmacology and psychotherapy?
Padberg, F., & Burkhardt, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18496-3.00001-x · Cited by 1
Bipolar Disorder: Diagnosis, Clinical Features, Outcome and Treatment
Burgess, J. L., Currie, A., Watson, S., Sharma, A., Cousins, D. A., Cookson, J., & McAllister-Williams, H. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.008 · Cited by 2
Vagus nerve stimulation for the management of depression and anxiety
Abd-Elsayed, A. A., Shiferaw, B. T., & Staats, P. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816996-4.00004-6 · Cited by 1
Klimkeit, E., Rinehart, N., May, T., Whelan, M., & Bradshaw, J. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00082-x · Cited by 1
Vagus nerve stimulation as a therapy for treatment resistant depression
Martínez, A. M. (2017) · RECERCAT (Consorci de Serveis Universitaris de Catalunya)
Metadata
- Authors
- Aaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M.
- Affiliations
- Rush University Medical Center (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 640-648
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2599051175
- Cited by
- 381
- References
- 26
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 34 · 2022: 40 · 2021: 39 · 2020: 43 · 2019: 47 · 2018: 37 · 2017: 8
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- treatment-resistant depression, vagus nerve stimulation, adjunctive therapy, response rate, remission, suicidality, bipolar depression, major depressive disorder, long-term outcomes
- MeSH terms
- Adult, Bipolar Disorder, Chronic Disease, Depressive Disorder, Major, Major Depressive Disorder, Electroconvulsive Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Registries, Treatment Outcome, Vagus Nerve Stimulation, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.